Table 2 Risk factors for 30-day mortality in patients treated with vancomycin or linezolid
Risk factors | Adjusted OR (95 % CI)a,b |
|---|---|
Vancomycin versus linezolid use | 2.56 (1.67–4.04) |
Year of hospitalization, 2005-2007 | 0.61 (0.44–0.83) |
Race (White) | 1.13 (0.66–1.90) |
Race (Black) | 1.23 (0.66–2.49) |
Hispanic ethnicity | 0.64 (0.39–1.01) |
VHA priority group 1 | 1.35 (0.71–2.52) |
VHA priority group 2–6 | 0.67 (0.34–1.34) |
Prior hospital admission | 2.58 (1.66–4.12) |
Outpatient intravenous antibiotics | 1.00 (0.60–1.64) |
>1 HCAP risk factor | 0.78 (0.53–1.15) |
Myocardial infarction | 1.02 (0.60–1.67) |
Congestive heart failure | 0.78 (0.55–1.12) |
Chronic obstructive pulmonary disease | 0.84 (0.59–1.21) |
Smoking | 0.84 (0.60–1.18) |
Cardiovascular medications | 1.04 (0.74–1.47) |
Anti-diabetic medications | 1.07 (0.74–1.54) |
Inhaled corticosteroids | 0.63 (0.38–1.01) |
Systemic corticosteroids | 0.73 (0.49–1.07) |
Pulmonary medications | 1.40 (0.94–2.10) |
Organ failure | 1.18 (0.80–1.73) |
Methicillin-resistant S. aureus | 0.68 (0.34–1.27) |
Streptococcus pneumoniae | 0.75 (0.27–1.80) |